Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

Intelligence powered by the Humanexa engine.

Therapeutic Area

Cystinosis

Therapeutic area intelligence for Cystinosis with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Companies

RegulatoryJuly 22, 2026

The FDA has accepted the New Drug Application (NDA) for Tiocystin (Tiopronin) submitted by Casper Pharma.

RegulatoryJune 30, 2026

The FDA has approved Tioprinin under NDA212927 for the treatment of cystinosis.

No catalysts indexed for this entity yet.

Newsletter

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.